US 12,213,959 B2
Use of 3-O-sulfamoyloxy-7β-methyl-d-homo-6-oxaestra-1,3,5(10),8(9)-tetraen-17a-one to treat breast cancer
Shamil Sionovich Ilyasov, Saint Petersburg (RU); Alexandr Grigorievich Shavva, Saint Petersburg (RU); and Svetlana Nikolaevna Morozkina, Saint Petersburg (RU)
Appl. No. 17/292,690
Filed by Natalia Eduardovna Iliasova, Saint Petersburg (RU)
PCT Filed Sep. 19, 2019, PCT No. PCT/RU2019/000651
§ 371(c)(1), (2) Date Jan. 28, 2022,
PCT Pub. No. WO2020/096487, PCT Pub. Date May 14, 2020.
Claims priority of application No. RU2018139337 (RU), filed on Nov. 8, 2018.
Prior Publication US 2022/0160676 A1, May 26, 2022
Int. Cl. A61K 31/352 (2006.01); A61P 35/00 (2006.01); C07D 311/78 (2006.01)
CPC A61K 31/352 (2013.01) [A61P 35/00 (2018.01); C07D 311/78 (2013.01)] 15 Claims
 
1. A compound, which is 3-O-sulfamoyloxy-7β-methyl-D-homo-6-oxaestra-1,3,5 (10),8 (9)-tetraen-17a-one of formula 2:

OG Complex Work Unit Chemistry